Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rehan M Hussain

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Expert Opinion on Biological Therapy|December 18, 2015
Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapyRehan M Hussain, Thomas A Ciulla
Ophthalmology|July 25, 2016
Purtscher's RetinopathyRehan M Hussain, Chi-Wah Yung
Expert Opinion on Emerging Drugs|August 1, 2017
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degenerationRehan M Hussain, Thomas A Ciulla
Expert Opinion on Investigational Drugs|March 14, 2022
KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseasesHudson D Stern, Rehan M Hussain
Clinical Ophthalmology (Auckland, N.Z.)|November 23, 2020
Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical EvidenceJie Gao, Rehan M Hussain, Christina Y Weng
Ophthalmic Surgery, Lasers & Imaging Retina|October 12, 2017
Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection FrequencyRehan M Hussain, Seenu M Hariprasad, Thomas A Ciulla
Therapeutic Delivery|October 3, 2024
Role of EYP-1901 in neovascular age-related macular degeneration and diabetic eye diseases: review of Phase I/II trialsAbrahem Sayed, Pranesh Ravichandran, Cecilia Canizela, et al.
International Ophthalmology Clinics|December 23, 2024
Tyrosine Kinase Inhibitors: The Next Chapter in Reducing Treatment Burden for Exudative Retinal Diseases?Pranesh Ravichandran, Cecilia Canizela, Abrahem Sayed, et al.
Expert Opinion on Biological Therapy|March 10, 2020
Voretigene neparvovec-rzyl for treatment of <i>RPE65</i>-mediated inherited retinal diseases: a model for ocular gene therapy developmentThomas A Ciulla, Rehan M Hussain, Audina M Berrocal, et al.
Expert Opinion on Biological Therapy|January 29, 2019
Complement inhibition as a therapeutic strategy in retinal disordersEnoch Kassa, Thomas A Ciulla, Rehan M Hussain, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Expert Opinion on Biological Therapy|December 18, 2015
Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapyRehan M Hussain, Thomas A Ciulla
Ophthalmology|July 25, 2016
Purtscher's RetinopathyRehan M Hussain, Chi-Wah Yung
Expert Opinion on Emerging Drugs|August 1, 2017
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degenerationRehan M Hussain, Thomas A Ciulla
Expert Opinion on Investigational Drugs|March 14, 2022
KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseasesHudson D Stern, Rehan M Hussain
Clinical Ophthalmology (Auckland, N.Z.)|November 23, 2020
Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical EvidenceJie Gao, Rehan M Hussain, Christina Y Weng
Ophthalmic Surgery, Lasers & Imaging Retina|October 12, 2017
Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection FrequencyRehan M Hussain, Seenu M Hariprasad, Thomas A Ciulla
Therapeutic Delivery|October 3, 2024
Role of EYP-1901 in neovascular age-related macular degeneration and diabetic eye diseases: review of Phase I/II trialsAbrahem Sayed, Pranesh Ravichandran, Cecilia Canizela, et al.
International Ophthalmology Clinics|December 23, 2024
Tyrosine Kinase Inhibitors: The Next Chapter in Reducing Treatment Burden for Exudative Retinal Diseases?Pranesh Ravichandran, Cecilia Canizela, Abrahem Sayed, et al.
Expert Opinion on Biological Therapy|March 10, 2020
Voretigene neparvovec-rzyl for treatment of <i>RPE65</i>-mediated inherited retinal diseases: a model for ocular gene therapy developmentThomas A Ciulla, Rehan M Hussain, Audina M Berrocal, et al.
Expert Opinion on Biological Therapy|January 29, 2019
Complement inhibition as a therapeutic strategy in retinal disordersEnoch Kassa, Thomas A Ciulla, Rehan M Hussain, et al.
Pageof 5